{
    "nct_id": "NCT01565291",
    "title": "A Preliminary Evaluation of the Amyloid Binding Properties, Pharmacokinetics and Safety of 18F-AV-45 in Healthy Elderly Volunteers and Patients With Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2012-05-11",
    "description_brief": "A preliminary study to test how florbetapir F 18 (18F-AV-45) acts in the brains and bodies of healthy elderly people and patients with Alzheimer's Disease (AD) by using a positron emission tomography (PET) scanner.",
    "description_detailed": "N/A",
    "phase": [
        "EARLY_PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "DIAGNOSTIC",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Subjects With AD",
                    "description": "Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination \\[MMSE\\] from 10 to 24)"
                },
                {
                    "id": "FG001",
                    "title": "Healthy Elderly Subjects",
                    "description": "Cognitively normal with MMSE of 29 or higher; age 50 years or older"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "16"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "16"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "15"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "16"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Subjects With AD",
                    "description": "Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination \\[MMSE\\] from 10 to 24)"
                },
                {
                    "id": "BG001",
                    "title": "Healthy Elderly Subjects",
                    "description": "Cognitively normal with MMSE of 29 or higher; age 50 years or older"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "16"
                        },
                        {
                            "groupId": "BG001",
                            "value": "16"
                        },
                        {
                            "groupId": "BG002",
                            "value": "32"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "75.8",
                                            "spread": "9.2"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "72.5",
                                            "spread": "11.56"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "74.3",
                                            "spread": "10.44"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "14"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "18"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "32"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Mean Cortical to Cerebellum SUVR",
                    "description": "Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the cerebellum gray matter. Total scan length was 200 min.",
                    "populationDescription": "4 subjects in AD group and 1 subject in the healthy elderly group were excluded due to poor placement and/or excessive movement in the scanner during the 200-minute procedure.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "SUVR",
                    "timeFrame": "50-60 min after injection",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Subjects With AD",
                            "description": "Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination \\[MMSE\\] from 10 to 24)"
                        },
                        {
                            "id": "OG001",
                            "title": "Healthy Elderly Subjects",
                            "description": "Cognitively normal with MMSE of 29 or higher; age 50 years or older"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "11"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "15"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.665",
                                            "spread": "0.175"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.246",
                                            "spread": "0.177"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Precuneus to Cerebellum SUVR",
                    "description": "Ratio of uptake in the precuneus to uptake in the cerebellum.",
                    "populationDescription": "4 subjects in AD group and 1 subject in the healthy elderly group were excluded due to poor placement and/or excessive movement in the scanner during the 200-minute procedure.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "SUVR",
                    "timeFrame": "50-60 min after injection",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Subjects With AD",
                            "description": "Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination \\[MMSE\\] from 10 to 24)"
                        },
                        {
                            "id": "OG001",
                            "title": "Healthy Elderly Subjects",
                            "description": "Cognitively normal with MMSE of 29 or higher; age 50 years or older"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "11"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "15"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.847",
                                            "spread": "0.237"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.300",
                                            "spread": "0.271"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "timeFrame": "AEs occuring within 3 days of injection. SAEs occuring within 30 days of injection",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Subjects With AD",
                    "description": "Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination \\[MMSE\\] from 10 to 24)",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 16,
                    "otherNumAffected": 0,
                    "otherNumAtRisk": 16
                },
                {
                    "id": "EG001",
                    "title": "Healthy Elderly Subjects",
                    "description": "Cognitively normal with MMSE of 29 or higher; age 50 years or older",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 16,
                    "otherNumAffected": 2,
                    "otherNumAtRisk": 16
                }
            ],
            "otherEvents": [
                {
                    "term": "HEADACHE",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA (9.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        }
                    ]
                },
                {
                    "term": "CLAUSTROPHOBIA",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA (9.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "GT60",
                "restrictiveAgreement": true
            },
            "pointOfContact": {
                "title": "Chief Medical Officer",
                "organization": "Avid Radiopharmaceuticals",
                "email": "clinicaloperations@avidrp.com",
                "phone": "215-298-0700"
            }
        }
    },
    "target_category": "N/A",
    "drug": [
        "florbetapir F 18 (18F-AV-45) \u2014 radioactive PET amyloid imaging tracer (branded Amyvid)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is florbetapir F 18 (18F-AV-45), a radioactive PET tracer developed to bind \u03b2\u2011amyloid plaques and provide an image-based estimate of amyloid/neurotic plaque density in the brain (i.e., a diagnostic imaging agent rather than a therapeutic). \ue200cite\ue202turn0search4\ue202turn0search5\ue201",
        "Act: Key extracted details \u2014 drug: florbetapir F 18 (18F-AV-45; marketed as AMYVID); type: radiolabeled small molecule PET tracer used for amyloid imaging; intended effect: detect/quantify amyloid in vivo and evaluate pharmacokinetics and safety. Because the trial evaluates imaging properties, pharmacokinetics and safety (diagnostic use), it does not test a disease-modifying biologic or small-molecule therapy, a cognitive enhancer, or an intervention for neuropsychiatric symptoms \u2014 therefore classification: 'N/A'. \ue200cite\ue202turn0search5\ue202turn0search0\ue201",
        "Reflect: Verification \u2014 florbetapir selectively binds \u03b2\u2011amyloid plaques and is used clinically as an adjunct diagnostic PET agent (FDA-approved as AMYVID for estimating amyloid neuritic plaque density); the study title/description (evaluation of amyloid binding properties, pharmacokinetics and safety by PET) confirms a diagnostic imaging study rather than a therapeutic trial, so 'N/A' is the appropriate category. \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Web search results used (short list of supporting sources): 1) FDA / Lilly AMYVID (florbetapir F 18) approval and label information (describes diagnostic indication and limitations). \ue200cite\ue202turn0search0\ue201 2) In vivo imaging trial describing 18F-AV-45 (florbetapir) PET accumulation in AD vs controls and reporting PK/safety data. \ue200cite\ue202turn0search5\ue201 3) Postmortem correlation study showing florbetapir binding correlates with \u03b2\u2011amyloid plaque burden (supports mechanism as amyloid imaging ligand). \ue200cite\ue202turn0search4\ue201 4) GMP synthesis/manufacturing note for 18F-AV-45 (supporting tracer identity and clinical use). \ue200cite\ue202turn0search3\ue201 5) Clinical-environment feasibility study using 18F-AV-45 for amyloid quantification. \ue200cite\ue202turn0search1\ue201"
    ],
    "agent_type": "N/A",
    "explanation_agent": []
}